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Metabolic control analysisThe methylerythritol phosphate (MEP) pathway of Plasmodium falciparum (P. falciparum) has
become an attractive target for anti-malarial drug discovery. This study describes a kinetic model
of this pathway, its use in validating 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) as
drug target from the systemic perspective, and additional target identiﬁcation, using metabolic con-
trol analysis and in silico inhibition studies. In addition to DXR, 1-deoxy-D-xylulose 5-phosphate
synthase (DXS) can be targeted because it is the ﬁrst enzyme of the pathway and has the highest ﬂux
control coefﬁcient followed by that of DXR. In silico inhibition of both enzymes caused large decre-
ment in the pathway ﬂux. An added advantage of targeting DXS is its inﬂuence on vitamin B1 and B6
biosynthesis. Two more potential targets, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase
and 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase, were also identiﬁed. Their inhibi-
tion caused large accumulation of their substrates causing instability of the system.
This study demonstrates that both types of enzyme targets, one acting via ﬂux reduction and the
other by metabolite accumulation, exist in P. falciparum MEP pathway. These groups of targets can
be exploited for independent anti-malarial drugs.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Plasmodium falciparum (P. falciparum) is a protozoan and the
chief cause of human malaria. Despite considerable scientiﬁc ad-
vances and the development of modern drugs, malaria still remains
one of the major causes of illness and mortality in the world. The
global expansion of the disease has been attributed mainly to thefailure of vector control programs and spread of resistance to chlo-
roquine [1–3], and other known anti-malarial drugs [4,5].
Three main strategies are presently attempted to control the
disease: (1) vaccination, (2) vector control, and (3) parasiticidal
drugs [6]. Of these, parasiticidal drugs are currently the main line
of disease control until vaccination or mosquito control can be
implemented more successfully. The emerging resistance to anti-
malarial drugs has even plagued this last line of defense. For these
reasons it is imperative that new lines of drugs be explored before
existing drugs lose too much efﬁcacy.
The malarial parasite relies on methylerythritol phosphate
(MEP) pathway for the synthesis of precursors for isoprenoids bio-
synthesis that are shown to be essential for it [7–11]. Even humans
need these precursors but they employ a different pathway (called
as mevalonate pathway) for their biosynthesis [12]. This makes
MEP pathway an attractive repertoire of anti-malarial drug targets,
but, as is known – not all enzymes of a pathway share the same
control over the functional aspects of a pathway [13–15], and a
systemic analysis is the rational approach to take.
The basis of any systemic analysis of a biochemical system in-
volves integration of the kinetics of the underlying enzymes and
associated biomolecules. Any such analyses could not have been
possible without the pioneering work of L. Michaelis and Maud L.
Menten who formulated one of the earliest models of enzymatic
catalysis [16]. Although, the original Michaelis–Menten equation
Fig. 1. Biochemical reactions in methylerythritol phosphate (MEP) pathway of P.
falciparum. DXS, 1-deoxy-D-xylulose 5-phosphate synthase; DXR, 1-deoxy-D-xylu-
lose 5-phosphate reductoisomerase; CDPMES, 4-(cytidine 50-diphospho)-2-C-
methyl-D-erythritol synthase; CDPMEK, 4-(cytidine 50-diphospho)-2-C-methyl-D-
erythritol kinase; MECPPS, 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase;
HMBPPS, 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase; HMBPPR, 1-
hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase.
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uses rapid equilibrium or steady state kinetics based on the mech-
anism and available evidence. Metabolic Control Analysis is a
mathematical framework that relates local behavior i.e., the behav-
ior of a single reaction considered in isolation, to global behavior of
the pathway it participates in [13–15]. It can highlight the relative
control exerted by each reaction on the pathway ﬂux and metabo-
lite concentrations, thus, providing a systemic view of any bio-
chemical system [17].
Reported in the paper is the construction of a kinetic model of P.
falciparum MEP pathway, which was subjected to Metabolic Con-
trol Analysis and the analysis of in silico inhibition of its enzymes.
In addition to verifying known targets in the pathway, the study
demonstrated two groups of potential drug targets whose mecha-
nisms of action are distinct. One group consists of those enzymes
that have high ﬂux control coefﬁcients for the ﬂux through the
pathway, and, led to large decrements in the pathway ﬂux when
inhibited in silico. The other group is formed of the enzymes that
have low ﬂux control coefﬁcients but have high ‘‘negative’’ concen-
tration control coefﬁcients for one or more metabolites of the path-
way. Thus, when these enzymes were inhibited in silico, they
caused a sharp increase in the concentrations of certain metabo-
lites, causing toxicity in cell. Such large accumulation of metabo-
lites is many a time correlated with cidal effect on the cell, and
thus, the enzymes causing it can serve as drug targets.
2. Methods
2.1. Construction of the kinetic model
2.1.1. Biochemical reactions of the pathway
Reactions of the MEP pathway were obtained from BioCyc data-
base speciﬁc for P. falciparum (PlasmoCyc) [18,19], and cross-
checked with that provided by malaria parasite metabolic path-
ways database (http://sites.huji.ac.il/malaria/). The pathway con-
sists of eight reactions in which twenty metabolites and seven
enzymes participate. Two hypothetical reactions (IPP_consump-
tion and DMAPP_consumption) and two hypothetical metabolites
(ipp_consumed and dmapp_consumed) were added to the model
to account for the consumption of isopentenyl pyrophosphate
(IPP) and dimethylallyl diphosphate (DMAPP) by the reactions out-
side MEP pathway. Thus, the total number of reactions considered
in the model was 10 in which a total of 22 metabolites participate
(see Fig. 1).
2.1.2. Rate equations describing the kinetics of the reactions
Rate equations govern the kinetics of the reactions, and were
obtained from literature data and/or derived from the rapid equi-
librium or steady state assumption. For the enzymes that are not
well characterized in P. falciparum, the equations were derived
from other organisms (as mentioned below) in which the mecha-
nism of those enzymes was elucidated. This was based on an
assumption that enzyme mechanisms are usually conserved across
the organisms.
2.2. 1-Deoxy-D-xylulose 5-phosphate synthase (DXS)
DXS catalyzes the condensation of pyruvate (PYR) and glyceral-
dehyde 3-phosphate (GAP) to yield 1-deoxy-D-xylulose 5-phos-
phate (DXP) with the release of CO2[20]. The reaction is
irreversible [21] with the enzyme working by an ordered mecha-
nism. During the reaction, PYR binds prior to GAP. The rate equa-
tion used to estimate the kinetic constants of the enzyme [20]
may not sufﬁce for the requirement of the rate equation for a ki-
netic model because the equation does not account for productinhibition which is indeed important in a kinetic model but not
in an in vitro assay. Thus, the rate equation for DXS-catalyzed reac-
tion in the model was derived with steady state assumption using
King–Altman method. The component reactions are shown in Fig. 2
(general reactions) and Fig. 3 (DXS-catalyzed component reac-
tions). An online tool (http://www.biokin.com/king-altman/sub-
mit.html) was used to derive the steady state rate equation as
manual calculation may go intractable with the increasing com-
plexity of the reactions. The online tool outputs the rate equation
in terms of individual rate constants. The equation was then con-
verted to the coefﬁcient form and subsequently to a form com-
posed entirely of kinetic constants by using general rules of
Cleland [22].
V ¼ Vf :A:B
KiaKB þ KBAþ KABþ KiaKBQKiq þ
KiaKBI
Kii
þ ABþ KBA:IKi þ
KABQ
Kiq
þ KABIKii
ð1Þ
Fig. 2. Component reactions of an enzyme-catalyzed reaction with ordered
mechanism. E, Enzyme; A, B: ﬁrst and second substrates of E; P, Q: ﬁrst and second
products of E; I, different types of hypothetical inhibitor, whose type is determined
by the form of enzyme it binds to.
Fig. 3. Component reactions of DXS-catalyzed reaction. E, Enzyme; PYR, Pyruvate;
GAP, glyceraldehyde 3-phosphate; DXP, 1-deoxy-D-xylulose 5-phosphate; I, differ-
ent types of hypothetical inhibitor, whose type is determined by the form of
enzyme it binds to.
Fig. 4. Component reactions of DXR-catalyzed reaction. E, Enzyme; DXP, 1-deoxy-
D-xylulose 5-phosphate; MEP, methylerythritol phosphate; I, different types of
hypothetical inhibitor, whose type is determined by the form of enzyme it binds to.
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versible reaction following ordered mechanism in the presence of a
non-competitive inhibitor. The inhibitor (I) can bind to the free en-
zyme (E) or to enzyme-A complex (E.A).
Comparing Fig. 2 and Fig. 3, reactants of DXS reactions are
mapped to equation (1) as follows: A = PYR; B = GAP; P = CO2;
Q = DXP; I = inhibitor; Vf = maximal velocity for the forward reac-
tion; Kia, Kiq, Kii = inhibition constants of A, Q and I from free en-
zyme (E) respectively (see [22] for deﬁnition of kinetic
constants); KA, KB, Ki = Michaelis constants for A, B and I respec-
tively. However, the derivation was continued with general equa-
tion for easy readability, and at the end, DXS reaction was
mapped on the rate equation.
In steady state systems, the relative concentration of a particu-
lar enzyme form may be expressed by several denominator terms,
and, often, a particular denominator term represents more than
one enzyme form. Thus, separate rate equations were derived for
different types of inhibitions. Their form remained similar though,
but varied with respect to the presence or absence of certain terms
in the equation.
For competitive inhibition, the component reactions would re-
main unchanged except that the reaction E:A:þ I $ E:A:I (when
mapped to DXS reaction:E:PYRþ I $ E:PYR:I) would not be there
because competitive inhibitor can only bind to free enzyme. Based
on this set of reactions, the rate equation would look as shown in
Eq. (2). This equation lacks a term KBAI=Ki in the denominator
when compared to the equation obtained in presence of non-com-
petitive inhibitor.
v ¼ Vf :A:B
KiaKB þ KBAþ KABþ KiaKBQKiq þ
KiaKBI
Kii
þ ABþ KABQKiq þ
KABI
Kii
ð2Þ
For uncompetitive inhibition, one of the component reactions
Eþ I $ E:I would be absent. All the other component reactions
would be same as that for non-competitive inhibition. The ratev ¼ Vf :PYR:GAP
Kia PYR:KGAP þ KGAP:PYRþ KPYR:GAP þ Kia PYR :KGAP :DXPKiq DXP þ Kia PYR:KGAP:a rxnlþ PYR:GAP þ KGAP:PYR:b rxnlþ
KPYR :GAP:DXP
Kiq DXP
þ KPYR:GAP:a rxnl
ð5Þequation derived on the basis of these reactions is shown in Eq.
(3). This equation lack the terms KiaKBIKii and
KABI
Kii
when compared to
the equation obtained in the presence of non-competitive
inhibitor.v ¼ Vf :A:B
KiaKB þ KBAþ KABþ KiaKBQKiq þ ABþ
KBA:I
Ki
þ KABQKiq
ð3Þ
Thus, the rate equations with competitive or uncompetitive
inhibitor, or without any inhibitor, are special cases of the rate
equation with non-competitive inhibitor.
Substituting a_rxn1 for I/Kii and b_rxn1 for I/Ki in the equation
for non-competitive inhibition Eq. (4), it becomes
v ¼ Vf :A:B
KiaKBþKBAþKABþ KiaKBQKiq þKiaKB:a rxnlþABþKBA:b rxnlþ
KABQ
Kiq
þKAB:arxnl
ð4Þ
In Eq. (4), a_rxn1 represents the competitive component and
was kept active (non-zero) only in the presence of a competitive
inhibitor, or, a non-competitive inhibitor (because non-competi-
tive inhibitor can bind to both free enzyme and to enzyme sub-
strate complex). Uncompetitive component is represented by
b_rxn1 and was kept active (non-zero) only in the presence of an
uncompetitive inhibitor, or, a non-competitive inhibitor. Thus,
the ﬁnal form of the rate equation for the reaction catalyzed by
DXS looks as is shown in Eq. (5).2.3. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (DXR)
Studies with Escherichia coli (E. coli) DXR indicated that it oper-
ates by an ordered sequential mechanism, with NADPH binding
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lyzing the reverse reaction, albeit at a lower rate [24]. Thus, the
component reactions of this enzyme-catalyzed reaction in the
presence of a non-competitive inhibitor (because that is the most
general case) would look as is shown in Fig. 4.
It was assumed that the inhibitor can bind only to free enzyme
or to enzyme-NADPH complex, but not enzyme-NADP complex. Fol-
lowing the steps discussed in previous section, the rate equation in
presence of a non-competitive inhibitor was obtained Eq. (6). In
the equation, A = NADPH; B = DXP; P =Methylerythritol phosphate
(MEP) and Q = NADP; I = inhibitor; Vf Vr= maximal velocity for the
forward and reverse reactions respectively; Keq = equilibrium con-
stant; Kia, Kib, Kip, Kiq, Kii = inhibition constants for A, B, P, Q and I
respectively; KA, KB0 KP, KQ = Michaelis constants for A, B, P and Q
respectively; Ki = dissociation constant of I from E.A complex;
Kmi = an arbitrary constant representing binding of I to an enzyme
form.v ¼
Vf AB PQKeq
 
KiaKB þ KBAþ KABþ Vf KQ PVrKeq þ
Vf KPQ
VrKeq
þ KiaKBIKii þ ABþ
Vf KQ AP
VrKeqKia
þ KBAIKi þ
KABQ
Kiq
þ KABIKii þ
Vf PQ
VrKeq
þ Vf KQ PIVrKeqKii þ
ABP
Kip
þ Vf KQ APIVrKeqKiaKi þ
Vf BPQ
VrKeqKib
þ Vf PQIVrKeqKmi
ð6ÞIn case when the inhibitor is a competitive one, the component
reactions would lack the reaction in which inhibitor binds to the
E.NADPH (i.e. E.A in case of general set of reactions) complex, keep-
ing rest all reactions unchanged. E:Aþ I $ E:A:I would be absent
and Eþ I $ E:I would be present.
The rate equation derived with these component reactions lacks
following terms in the denominator as compared to that obtained
in the presence of a non-competitive inhibitor: KBAIKi ,
Vf KQ API
VrKeqKiaKi
, and
Vf PQI
VrKeqKmi
.
In the presence of an uncompetitive inhibitor, the component
reactions lack the reaction in which inhibitor binds to the free en-
zyme (Eþ I $ E:I would be absent). Rest all component reactions
remain same as that for non-competitive inhibi-
tion.E:NADPH þ I $ E:NADPH:I would be present.
The rate equation obtained with these component reactions
lacks the following terms in the denominator when compared to
that obtained in the presence of non-competitive inhibitor: KiaKBIKii ,KABI
Kii
and Vf KQ PIVrKeqKii .
Thus, the rate equations with competitive or uncompetitive
inhibitor, or without any inhibitor, are special cases of the rate
equation with non-competitive inhibitor. Substituting a_rxn2 for
I/Kii and b_rxn2 for I/Ki and I/Kmi in the equation for non-competi-
tive inhibition Eq. (6), it becomes Eq. (7).
v ¼
Vf ðAB PQKeqÞ
KiaKB þ KBAþ KABþ Vf KQ PVrKeq þ
Vf KPQ
VrKeq
þ KiaKB:a rxn2
þABþ Vf KQ APVrKeqKia þ KBA:b rxn2þ
KABQ
Kiq
þ KAB:a rxn2þ Vf PQVrKeq
þ Vf KQ P:a rxn2VrKeq þ ABPKip þ
Vf KQ AP:b rxn2
VrKeqKia
þ Vf BPQVrKeqKib þ
Vf PQ :b rxn2
VrKeq
ð7Þ
n the above equation Eq. (7), a_rxn2 represents the competitive
component and was kept active (non-zero) only in the presence of
a competitive inhibitor, or, a non-competitive inhibitor (because
non-competitive inhibitor can bind to both free enzyme and to en-
zyme substrate complex). Uncompetitive component is repre-
sented by b_rxn2 and was kept active (non-zero) only in the
presence of an uncompetitive inhibitor, or, a non-competitive
inhibitor. Thus, the ﬁnal form of the rate equation for the reaction
catalyzed by DXR looks as is shown in Eq. (8).v ¼
Vf NADPH:DXP  MEP:NADPKeq
 
Kia NADPH:KDXP þ KDXP:NADPH þ KNADPH:DXP
þ Vf KNADP :MEPVrKeq þ
Vf KMEP :NADP
VrKeq
þ Kia NADPH:KDXP:a rxn2
þNADPH:DXP þ Vf KNADP :NADPH:MEPVrKeqKia NADPH þ KDXP:NADPH:b rxn2
þ KNADPH :DXP:NADPKiq NADP þ KNADPH:DXP:a rxn2þ
Vf MEP:NADP
Vf Keq
þ Vf KNADP :MEP:a rxn2VrKeq þ NADPH:DXP:MEPKip MEP
þ Vf KNADP :NADPH:MEP:brnx2VrKeqKia NADPH þ
Vf DXP:MEP:NADP
VrKeqKib DXP
þ Vf MEP:NADP:b rnx2VrKeq
ð8ÞAfter re-arranging Eq. (8) so as to put all the inhibition terms
(terms containing a_rxn2 and b_rxn2) at the end of the denomina-
tor, the equation becomes as shown in the Eq. (9).
v ¼
Vf NADPH:DXP  MEP:NADPKeq
 
Kia NADPH:KDXP þ KDXP:NADPH þ KNADPH:DXP þ Vf KNADP :MEPVrKeq
þ Vf KMEP :NADPVrKeq þ NADPH:DXP þ
Vf KNADP :NADPH:MEP
VrKeqKia NADPH
þ Vf MEP:NADPVrKeq
KNADPH :DXP:NADP
Kiq NADP
þ NADPH:DXP:MEPKip MEP
þ Vf DXP:MEP:NADPVrKeqKib DXP þ Kia NADPH:KDXP:a rxn2
þKNADPH:DXP:a rnx2þ Vf KNADP :MEP:a rxn2VrKeq
þKDXP:NADPH:b rxn2
þ Vf KNADP :NADPH:MEP:brnx2VrKeqKia NADPH þ
Vf MEP:NADP:b rnx2
VrKeq
ð9Þ2.4. 4-(Cytidine 50-diphospho)-2-C-methyl-D-erythritol synthase
(CDPMES)
Pulse chase experiments established that the synthesis of 4-
(cytidine 50-diphospho)-2-C-methyl-D-erythritol (CDPME) through
this reaction involves an ordered sequential mechanism with man-
datory initial binding of CTP [25]. To derive the rate equation for
the kinetics of this enzyme, the CTP concentration was assumed
to be constant and in large excess, so that its effect on the rate
equation can be ignored. This simpliﬁcation was assumed because
CTP being a major cellular metabolite, its concentration would be
tightly controlled by the cellular machinery and would not vary
much in the time scale chosen for this modeling study. After the
simpliﬁcation, the rate equation reduces to a simple one substrate
Michaelis–Menten equation as shown in Eq. (10).
v ¼
Vf : MEPKMEP
1þ MEPKMEP
ð10Þ
Modifying the equation to include product inhibition, and the
terms to account for competitive, uncompetitive and non-compet-
itive inhibition, the resulting equation would become as Eq. (11). In
this equation, a_rxn3 = I/Kis and b_rxn3 = I/Kii; a_rxn3 referring to
the competitive component which is active (non-zero) in the
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tor, and, b_rxn3 referring to the uncompetitive component which
is active (non-zero) in the presence of an uncompetitive inhibitor,
or, a non-competitive inhibitor.
v ¼
Vf : MEPKMEP
1þ MEPKMEP þ CDPMEKCDPME þ a rxn3þ b rxn3: MEPKMEP
ð11Þ2.5. 4-(Cytidine 50-diphospho)-2-C-methyl-D-erythritol kinase
(CDPMEK)
The enzyme follows Michaelis–Menten kinetics [26] where ATP
contributes the phosphate group for the phosphorylation of
CDPME to synthesize 2-phospho-4-(cytidine 50-diphospho)-2-C-
methyl-D-erythritol (CDPMEP) and gets converted to ADP in the
process. Since, ATP and ADP concentration remains constant over
a long time scale, they are assumed to remain constant during
the simulation. Moreover, assuming their concentration to be pres-
ent in large excess in the cell, their effect on the rate equation was
ignored. This simpliﬁed the rate equation to a simple one substrate
Michaelis–Menten equation. Adding the terms for product inhibi-
tion, and, terms accounting for enzyme inhibition, the ﬁnal rate
equation appears as shown in Eq. (12). In the Eq. (12), a_rxn4 = I/
Kis and b_rxn4 = I/Kii and have the same meaning as discussed
previously.
v ¼
Vf : CDPMEKCDPME
1þ CDPMEKCDPME þ CDPMEPKCDPMEP þ a rxn4þ b rxn4: CDPMEKCDPME
ð12Þ2.6. 2-C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase (MECPPS)
MECPPS follows Michaelis–Menten kinetics and results in the
synthesis of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MEC-
PP). For simplicity, CMP concentration was assumed to be constant
and in large excess for the time scale of this model. This reduced
the rate equation to a one substrate Michaelis–Menten equation.
Including the terms for product inhibition, and inhibition by chem-
ical inhibitors of different types (competitive, uncompetitive and
non-competitive), the ﬁnal rate equation appears as shown in Eq.
(13).
v ¼
Vf : CDPMEPKCDPMEP
1þ CDPMEPKCDPMEP þ MECPPKMECPP þ a rxn5þ b rxn5: CDPMEPKCDPMEP
ð13Þ2.7. 1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HMBPP)
synthase (HMBPPS)
The enzyme follows Michaelis–Menten kinetics, and after
ignoring the effect of protein dithiol and protein disulﬁde on the
rate equation, it reduced to a simple one substrate Michaelis–
Menten equation. Including terms for product inhibition and
inhibition by chemical inhibitor of various types (competitive,
uncompetitive, and non-competitive), the equation appears as
shown in Eq. (14).
v ¼
Vf : MECPPKMECPP
1þ MECPPKMECPP þ HMBPPKHMBPP þ a rxn6þ b rxn6: MECPPKMECPP
ð14Þ2.8. 1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HMBPP)
reductase (HMBPPR)
This enzyme catalyzes two reactions, one in which HMBPP gets
reduced to IPP, and, the second in which HMBPP gets reduced to
DMAPP. The ratio of IPP to DMAPP produced by the enzyme wasfound to be 6.3:1 [27]. As most of the reductase enzymes work
by ordered sequential mechanism [21], this enzyme was also as-
sumed to follow the same mechanism. In such enzymes, NADPH
binds to the free enzyme, and the enzyme-NADPH complex binds
to the second substrate. Thus, in case of HMBPPR, HMBPP was as-
sumed to bind to the enzyme-NADPH complex. In the reverse reac-
tion, NADP binds to the free enzyme, and then the substrate for the
reverse reaction (IPP or DMAPP) binds to enzyme-NADP complex.
Thus, the two substrates for the reverse reaction, IPP and DMAPP
compete with each other for binding to the enzyme-NADP complex.
The rate equation for this enzyme was derived using the rapid
equilibrium. The equilibria between various enzyme forms are
shown in Fig. 5. Based on the equilibria, rate equations were de-
rived using rapid equilibrium assumption by following the steps
outlined by Segel [22] .
Eq. (15) and (16) show the rate equations of reactions-7 and 8
respectively. The two equations are similar except that the numer-
ator of Eq. (15) contains V7r : NADPKNADP :
IPP
KIPP
term to be subtracted from
V7f : NADPHKNADPH :
HMBPP
KHMBPP
, while Eq. (16) contains a term V8r : NADPKNADP :
DMAPP
KDMAPP
to
be subtracted from V8f : NADPHKNADPH :
HMBPP
KHMBPP
in the numerator. In addition,
Eq. (16) is multiplied with a factor (1/6.3) so that IPP and DMAPP
are produced in the ratio observed experimentally [27].
v7 ¼
V7f : NADPHKNADPH :
HMBPP
KHMBPP
 V7r : NADPKNADP : IPPKIPP
1þ NADPHKNADPH þ NADPKNADP þ NADPHKNADPH : HMBPPKHMBPP
þ NADPKNADP : IPPKIPP þ NADPKNADP : DMAPPKDMAPP þ a rxn7þ b rxn7: NADPHKNADPH
ð15Þ
v8 ¼ 16:3
V8f : NADPHKNADPH :
HMBPP
KHMBPP
 V8r : NADPKNADP : DMAPPKDMAPP
1þ NADPHKNADPH þ NADPKNADP þ NADPHKNADPH : HMBPPKHMBPP
þ NADPKNADP : DMAPPKDMAPP þ NADPKNADP : DMAPPKDMAPP þ a rxn8þ b rxn8: NADPHKNADPH
2
66664
3
77775
ð16Þ2.9. Hypothetical reactions
The two hypothetical reactions added to the model to account
for the consumption of end-products of the MEP pathway (IPP
and DMAPP), were assigned mass action kinetics of the form
shown in Eq. (17) and (18) respectively. These equations enabled
a concentration dependent consumption of the end-products as
can be normally expected in cellular environment. In the Eq. (17)
and (18), k9 and k10 are the rate constants of the respective
reactions.
v9 ¼ k9:IPP ð17Þ
v10 ¼ k10:DMAPP ð18Þ2.9.1. Parameters of the model
Not all of the enzymes of the pathway are well characterized in
P. falciparum, and thus, the kinetic parameters of many of the en-
zymes were not available for P. falciparum.
To workaround this problem, a sequence similarity based ap-
proach was employed. The approach uses amino acid sequence
comparison, and is based on the assumption that the enzymes hav-
ing high sequence similarity would have similar 3-dimensional
structure, and thus, would have similar kinetic properties, i.e. their
kinetic parameters (such as Vmax, KM, etc.) would be similar. Hence,
for all the P. falciparum enzymes whose kinetic data were unavail-
able, BLAST-P was performed using their amino acid sequences as
queries to search for similar protein sequences, which was not suc-
cessful. Hence, PSI-BLAST was performed, and the sequence show-
ing highest sequence similarity (as estimated by the BIT score from
Fig. 5. Component reactions of HMBPPR-catalyzed reactions. E, Enzyme; HMBPP, 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate; IPP, isopentenyl pyrophosphate;
DMAPP, dimethylallyl diphosphate; I, different types of hypothetical inhibitor, whose type is determined by the form of enzyme it binds to.
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tract the kinetic data in the model. In many cases, the KM values of
the products (substrates for the reverse direction) of the reactions
were unavailable. These KM values were made equal to 10  KM of
the same metabolite for the enzyme that uses this metabolite as a
substrate. The initial concentrations of variable metabolites were
majorly kept equal to twice their KM values (see Supplementary
Table S1 for kinetic parameters used in MEP pathway model). In
case, a metabolite participates in two or more reactions, its initial
concentration was set to twice of the highest KM value of that
metabolite. Same was done for all the metabolites whose concen-
trations were kept ﬁxed, and thus, were parameters of the model
(see Supplementary Table S2).
2.9.2. Simulation of the model
The model was expressed in standard System Biology Markup
Language (SBML) format, which also facilitates its use in various
biochemical network simulators. Two publicly available simulators
– Copasi [28] and CellDesigner [29] were used for preliminaryanalysis of the model. CellDesigner was used to study the time evo-
lution of the system, and Copasi was used for ﬁnding the steady
state and performing steady state analysis. The detailed simula-
tions, in particular, the simulation of the inhibition of the enzymes
of the pathway was done by writing programs in Matlab [30]. Mat-
lab toolboxes – SBML toolbox [31] and Systems Biology toolbox
[32] were used, wherein the model expressed in SBML format
was ﬁrst converted to the native format of Matlab (SBmodel (a
Matlab structure)), and was then used for further simulations.
2.10. Sensitivity analysis
‘‘Sensitivity analysis’’ utility of Copasi [28] was used to perform
sensitivity analysis so as to assess the effects of the parameters on
the variables (ﬂuxes and internal metabolite concentrations) of the
model.
2.11. Metabolic control analysis
The function ‘‘Metabolic Control Analysis" in Copasi [28] was
used to perform this analysis.
2.12. In silico inhibition of the enzymes
Effect of inhibition of the enzymes of the pathway were simu-
lated in silico by including inhibition terms in the rate equations
of the corresponding reactions, and then performing a steady state
simulation of the model. All the rate equations in the basic model
itself contain the inhibition terms but they were all initialized to
zero (see Methods section for details). While simulating the inhibi-
tion of an enzyme, the corresponding inhibition terms (ratio of
inhibitor concentration to the inhibitor constant (I/KI)) were iter-
ated from 0–100 and steady state computed at each iteration. In
case steady state could not be found with the given set of param-
eters and initial conditions, a time course simulation was per-
formed and the metabolite concentrations and ﬂuxes were stored
at each time step. For certain simulations, however, Copasi [28]
was used as the solver because Matlab [30] program failed to reach
steady state solution.
Table 2
Steady state concentrations of the variable metabolites of MEP pathway model.
Metabolite Concentration (in mM)
CDPME 0.00379834
CDPMEP 0.0848652
DMAPP 0.000106456
DXP 0.129072
HMBPP 1.37292
IPP 0.000670669
MECPP 2.94916
MEP 0.00588235
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3.1. Time evolution of the system
Concentration of mainly two metabolites – MECPP and HMBPP
showed initial turbulence but later all of them settled to their
respective steady state concentrations (Fig. 6). Fluxes of the path-
way also showed similar behavior (Fig. 7) indicating the attain-
ment of steady state.
3.2. Steady state solution
MEP pathway model attained a steady state with the given set
of parameters and the initial conditions. The resultant ﬂuxes and
all the metabolite concentrations were found to be comparable
to the physiological range (Table 1 and Table 2). At steady state,
the ratio at which IPP and DMAPP were synthesized was equal to
6.3:1 as was observed experimentally [27].
3.3. Sensitivity analysis
Sensitivity analysis is an important step in the modeling process
to ascertain the dependence of the model variables on the param-
eter values chosen. Brieﬂy, the ratios between change in a model
output (e.g. concentration of a metabolite) and the perturbation
on parameters (e.g. Michaelis constant of an enzyme) are com-
puted, which reﬂect the sensitivity of the model on a parameter
[33,34]. Since, MEP pathway model was built with signiﬁcant
amount of data taken from other organisms (in cases where the
values were unavailable for P. falciparum), sensitivity analysis be-
comes critical in assessing the results obtained from the simula-
tions of this model. It was observed that the concentrations of
the variable metabolites and the ﬂuxes through the reactions wereTable 1
Steady state ﬂuxes through MEP pathway model.
Enzyme (Reaction step) Fluxes (mmol/min/mg)
DXS (Reaction-1) 0.000777125
DXR (Reaction-2) 0.000777125
CDPMES (Reaction-3) 0.000777125
CDPMEK (Reaction-4) 0.000777125
MECPPS (Reaction-5) 0.000777125
HMBPPS (Reaction-6) 0.000777125
HMBPPR (Reaction-7) 0.000670669
HMBPPR (Reaction-8) 0.000106456
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Fig. 7. Time evolution of MEP pathway model with respect to the ﬂuxes through
the reactions.mainly sensitive to the parameter values of reactions-1, 2, 7 and 8
(data not shown). They were also sensitive to the initial concentra-
tion of following boundary metabolites – PYR, GAP, NADPH and
NADP (data not shown). It is interesting to note that the kinetic
parameters of none of the above reactions were available for P. fal-
ciparum, and thus, were approximated from other organisms (see
Supplementary Table S1 for details). A cue can be taken from this
observation, and the future experiments be aimed at investigating
these reactions in P. falciparum. This would not only help gain dee-
per insight into the dynamics of the pathway, but can also indicate
the systemic signiﬁcance of these reactions.3.4. Metabolic control analysis
The ﬁrst enzyme of the pathway, DXS has highest ﬂux control
coefﬁcient (=0.97) followed by that of DXR (=0.03). DXS was earlier
shown to be one of the rate-limiting enzymes of MEP pathway in
Arabidopsis and tomato plants [35,36]. Overexpression of DXR in
A. thaliana caused an enhanced ﬂux through MEP pathway, indicat-
ing high ﬂux control coefﬁcient for DXR as well [37]. Other en-
zymes of the pathway had signiﬁcantly lower ﬂux control
coefﬁcient as compared to these two enzymes. HMBPPR has sec-
ond highest ﬂux control coefﬁcient for its own reactions and for
the hypothetical reactions accounting for consumption of IPP and
DMAPP by reactions not accounted for in the model.3.5. In silico inhibition of the enzymes
In silico inhibition of all the enzymes of the network was per-
formed sequentially, and their effect on the steady state ﬂuxes
and concentration of the metabolites was assessed. Effects of var-
ious types of inhibitors (competitive, uncompetitive and non-com-
petitive) were addressed.
As mentioned earlier, there are two basic metabolic methods of
killing a pathogen – by decreasing ﬂux through an essential path-
way to a level unsustainable by the pathogen, or, by increasing a
metabolite concentration to toxic levels [38]. The former can be
achieved by inhibiting an enzyme having high ﬂux control coefﬁ-
cient (FCC), whereas the latter can be achieved by the inhibition
of an enzyme with a small ﬂux control coefﬁcient [38]. An enzyme
with high negative concentration control coefﬁcient (CCC) for a
certain metabolite, when inhibited, can serve as a good candidate
to bring about enormous increase in that metabolite concentration.
3.6. Enzyme inhibitions causing decrease in ﬂux through the pathway
As discussed earlier, the reactions catalyzed by DXS and DXR
practically share the full control of the ﬂux through MEP pathway.
Thus, their inhibition was expected to cause a large decrement in
the ﬂux through the pathway (see Table 3).
Table 3
Results of in silico inhibition of the enzymes that led to decrement in the ﬂux through MEP pathway.
Enzyme inhibited % decrement in ﬂux due to inhibition (I/KI = 100) Supporting experimental data
Competitive Uncompetitive Non-competitive
DXS 96.11 96.04 97.99 Ketoclomazone inhibits DXS of Chlamydomonasa
DXR 86.20 24.99 86.30 Fosmidomycin is a well known inhibitor of DXRb
a Mueller et al. [40].
b Proteau [23].
Fig. 8. BLAST2 generated amino acid sequence alignment of P. falciparum DXS (along x-axis) with E. coli DXS (along y-axis).
Fig. 9. BLAST2 generated amino acid sequence alignment of P. falciparum DXR (along x-axis) with E. coli DXR (along y-axis).
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At I/KI = 100, the percent decrement caused in the ﬂux through
the pathway was about 96% for both competitive and uncompeti-
tive inhibition and about 98% for non-competitive inhibition. It,
thus, appeared from metabolic control analysis and in silico inhibi-
tion study that DXS can be a good candidate for anti-malarial drug
target, targeting which would cause deleterious effect on the ﬂux
through the essential MEP pathway in P. falciparum. Targeting
DXS has an additional advantage of inﬂuencing vitamin B1 and
B6 biosynthesis as well because the product of DXS-catalyzed reac-
tion also serves as a precursor in this pathway [6,39].
Ketoclomazone, a breakdown product of the herbicide clomaz-
one is known to inhibit DXS of Chlamydomonas sp. with IC50 of
approximately 0.1 mM [40]. Calculating KI using the relation be-
tween KI and IC50 (see Eq. (19), where S = PYR concentra-tion = 0.88 mM; KS =Michaelis constant for PYR = 0.44 mM;
KI = Inhibition constant of the inhibitor (ketoclomazone in this
case); IC50 = inhibitor concentration that reduces the rate of the
reaction to 50% of its uninhibited value = 0.1 mM, we get Eq. (20).
KI ¼ IC50
1þ SKS
  ð19Þ
KI ¼ 0:11þ 0:880:44
  ¼ 0:1
1þ 2 ¼
0:1
3
¼ 0:033mM ð20Þ
Hence, if the inhibitor is a competitive one, a_rxn1 would be set
equal to I/KI = 0.1/0.033 = 3.03 (I is set as equal to IC50 i.e. the con-
centration of inhibitor that caused 50% decrement in the rate of
the reaction as compared to the uninhibited rate). Percent decre-
ment was calculated as per Eq. (21).
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Fig. 10. Accumulation of metabolites due to in silico uncompetitive inhibition of
MECPPS with I/KI = 5.
0 1 2 3 4 5 6 7 8 9 10
x 105
0
0.5
1
1.5
2
2.5
3
Time (min)
C
on
ce
nt
ra
tio
n 
(m
M
)
DXP
MEP
CDPME
CDPMEP
MECPP
HMBPP
IPP
DMAPP
Fig. 11. Concentration of variable metabolites plotted against time during in silico
uncompetitive inhibition of MECPPS with I/KI = 4.
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¼ ðuninhibitedflux-inhibitedfluxÞ
uninhibitedflux
 100 ð21Þ
The calculation showed that percent decrement in the ﬂux
through DXS-catalyzed reaction was about 42%. This value is pretty
close to 50% considering that IC50 at this inhibitor concentration
was observed in Chlamydomonas sp. but not in P. falciparum. Con-
sidering other cases when the inhibitor acts as an uncompetitive
inhibitor or a non-competitive inhibitor, the percent decrements
observed in the ﬂux were about 42% and 60%, respectively. As ex-
pected, assuming inhibition to be non-competitive, the percent
decrement caused in the rate of the reaction was highest, but,
was still close to IC50 value (competitive inhibition) indicating no
advantage for the non-competitive inhibitor in this case.
Three dimensional structure of E. coli DXS has already been
published [41]. As P. falciparum DXS shares a good sequence simi-
larity (bit score = 205 with E-value = 7e-57) (Fig. 8) with E. coli DXS,
ascertained by performing BLAST2, the structure of E. coli DXS can
be mapped to P. falciparum DXS, and be used for structure based
competitive inhibitor designing.
3.8. Inhibition of DXR
The percent decrement caused in the ﬂux through the pathway
due to competitive and non-competitive inhibition was about 86%and due to uncompetitive inhibition was about 25%. Potential of
DXR as a drug target have long been established and the present
study has further conﬁrmed it from systems perspective. Fosmido-
mycin, for example, is a well-known mixed inhibitor of DXR with
KI = 38nM [23]. Recent studies have more accurately deﬁned it as
a slow, tight-binding inhibitor that displays two inhibition modes,
an initial step competitive with DXP and another non-competitive
with DXP [21]. Apart from P. falciparum DXR [10,42], fosmidomycin
was also shown to inhibit Arabidopsis thaliana and Hordeum vulgare
(barley) DXR [40].
A BLAST2 performed with P. falciparum DXR and E. coli DXR [43]
as the ﬁrst and second sequence respectively showed a good se-
quence similarity (bit score = 269 with E-value = 1e-76) (Fig. 9).
This implied that the structure of E. coli DXR can be mapped to P.
falciparum DXR, and thus, can be used to get an insight into the
structural features of DXR fosmidomycin complex, and, for struc-
ture based drug designing.
3.9. Enzyme inhibitions causing increase in the concentration of
metabolite(s)
Alternate strategy of killing a pathogen is by increasing the con-
centration of a toxic metabolite inside the cell [38]. Enzymes hav-
ing high negative CCC towards the metabolite(s) that could to be
toxic to a cell and low FCC would be ideal enzymes for this pur-
pose. Inhibiting such enzymes would cause the level of toxic
metabolite to rise, and, due to low FCC of the enzyme, there would
not be neutralizing change in ﬂux.
3.10. Inhibition of MECPPS
Competitive inhibition of this enzyme with a maximum I/
KI = 100 caused negligible alteration in the ﬂux through the path-
way (=0.0004%). Uncompetitive and non-competitive inhibition,
however, led to unstable steady states (as assessed by Copasi
[28]) at I/KIP 5. The time course simulation with I/KI = 5 for both
uncompetitive and non-competitive inhibition showed a steep in-
crease in the concentration of certain metabolites of the pathway,
highest change being in the CDPMEP concentration (see Fig. 10 and
Fig. 11). This was intuitive because there is no other reaction where
CDPMEP can be consumed (at least in the model, and also inside
the P. falciparum cellular milieu [18,44]). Other metabolites that
showed steep increase in the concentration were DXP, MEP and
CDPME, but, this was observed at higher I/KI ratio. All these metab-
olites are synthesized upstream of MECPPS reaction, and they
accumulated as a result of drop in the activity of this enzyme. Ex-
cept DXP, which acts as a precursor for the biosynthesis of vitamins
B1 and B6, other listed metabolites are not consumed by any other
reaction in P. falciparum.
If MECPPS would have had a high ﬂux control coefﬁcient, it
would have inﬂuenced the ﬂux through the pathway so that less
CDPMEP is synthesized and thus, there would not had been any
accumulation of CDPMEP. Thus, even this enzyme seems to be a
potential drug target, the inhibition of which would cause a huge
accumulation of metabolite that may lead to instability in the net-
work and will cause deleterious effect on the organism. Further
experimental work would be able to throw insight into the actual
cellular effect of the inhibition of this enzyme.
For the purpose of structure based inhibitor generation [45,46],
chemicals were designed for MECPPS and their dissociation con-
stants and IC50 were available in literature [47]. The IC50 of CDP
was also tested in the same study and was found to be equal to
7.3 mM. Deriving the KI of CDP from substrate concentration
(CDMEP), its Michaelis constant, and the IC50 value of the inhibitor
according to the relation shown in Eq. (19), KI was computed as
equal to 5.57 mM.
0 1 2 3 4 5 6 7 8 9 10
x 107
0
0.5
1
1.5
2
2.5 x 10
4
Time (min)
C
on
ce
nt
ra
tio
n 
(m
M
)
DXP
MEP
CDPME
CDPMEP
MECPP
HMBPP
IPP
DMAPP
Fig. 13. Accumulation of metabolites due to in silico uncompetitive inhibition of
HMBPPS with I/KI = 2.
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Fig. 14. Concentration of variable metabolites plotted against time during in silico
uncompetitive inhibition of HMBPPS with I/KI = 1.
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CDP acts as a competitive inhibitor, a_rxn5 was made equal to
IC50/KI = 7.3 mM/5.57 mM = 1.31. The inhibitor at this concentra-
tion did not alter the ﬂux through the pathway at all, but, caused
an increase in CDPMEP concentration, albeit a small one. A BLAST2
performed with P. falciparum MECPPS and E. coli MECPPS (taken
from PDB ID: 2GZL) as the ﬁrst and second sequence respectively
showed a good sequence similarity (bit score = 99.8 with E-va-
lue = 3e-26) (Fig. 12). This implied that the structure of E. coliMEC-
PPS can be used as template for P. falciparumMECPPS and thus, can
be used for structure based drug designing.
3.11. Inhibition of HMBPPS
The inhibition pattern of this enzyme was similar to that ob-
tained by the inhibition of MECPPS. Competitive inhibition with a
maximum I/KI = 100 did not affected the ﬂux through the pathway
at all but did caused an increase in the steady state concentration
of MECPP (substrate of HMBPPS). Uncompetitive and non-compet-
itive inhibition resulted in unstable steady states (as assessed by
Copasi [28]) of the system with I/KIP 2 (see Fig. 13 and Fig. 14).
The cause for instability was the increase in concentrations of cer-
tain metabolites of the pathway. Highest increase was indeed ob-
served in the concentration of the substrate of HMBPPS (i.e.
MECPP concentration); other metabolites that showed increase in
concentration (CDPMEP, CDPME, MEP and DXP) were all located
upstream of HMBPPS reaction. Thus, this enzyme should also be
added to the list of potential drug targets in MEP pathway for
the reasons described above.
3.12. Inhibition of CDPMES, CDPMEK and HMBPPR
Inhibition of the enzymes CDPMES, CDPMEK and HMBPPR also
resulted in the increase of the concentration of metabolites, mainly
their substrate concentrations, but, they did not caused instability
to the system. Thus, these enzymes may not be the drug targets of
choice until the inhibition caused to them is very high.
MEP pathway, which consists of eight enzyme-catalyzed reac-
tions, wherein the catalysis is brought about by seven enzymes,
is an essential pathway for P. falciparum. Kinetic modeling, meta-
bolic control analysis, and in silico inhibition of the enzymes of this
pathway showed that four out of seven enzymes could be good
candidates for drug targets. They are, two enzymes – DXS and
DXR, which are the ﬁrst two enzymes in the pathway, and their
inhibition caused a large decrement in the ﬂux through the path-
way making the synthesis of the end-products – IPP and DMAPPFig. 12. BLAST2 generated amino acid sequence alignment of P. falcipalmost zero. On the other hand, the other two potential drug tar-
gets, MECPPS and HMBPPS led to large accumulation of their sub-
strate metabolite (and in some cases all the metabolites lying
upstream in the pathway), and caused instability of the system.
So, the response of the former and the latter group of enzymes to
inhibition were different, and can be exploited to make indepen-
dent anti-malarial drugs. The effectiveness of such drugs wouldarum MECPPS (along x-axis) with E. coli MECPPS (along y-axis).
2816 V.K. Singh, I. Ghosh / FEBS Letters 587 (2013) 2806–2817not be limited to P. falciparum, they can be applied to other patho-
gens also which appoint MEP pathway for the synthesis of precur-
sors of isoprenoids. The possible caveat in this entire scheme is
that the two groups of enzymes should not be targeted simulta-
neously because in that case there is a chance of annihilating the
effect of each other’s inhibition, and overall neutralization of the
effect of drugs.
The kinetic model of this pathway was built with certain
assumptions, major being that many kinetic constants was taken
from organisms other than P. falciparum based on sequence simi-
larity. Such assumption would deﬁnitely have an impact on the re-
sults of the simulation but they would most likely cause the
quantitative shift. The qualitative behavior of the system would re-
main same as exhibited by the current model. The good agreement
of the model predictions with the available experimental data on
the inhibition of various enzymes, in a way, indicated the validity
of the model. A recent review [48] emphasized on the need of in sil-
ico inhibition study to identify new set of biological target proteins
in metabolic pathways. Present study further stressed that uncom-
petitive and non-competitive inhibitors cause instability in the sys-
tem more often than competitive inhibitors as is evident from the
difference in the dynamics of competitive vs. uncompetitive or
non-competitive inhibition of MECPPS- and HMBPPS-catalyzed
reactions. However, it is noteworthy that it is chemically challeng-
ing to design such inhibitors.
4. Conclusions
In conclusion, present in silico study demonstrated that even a
eukaryotic pathogen like P. falciparum is amenable to systems level
analysis of biochemical pathway, and, helped identify new drug
targets. In addition, the present study validated the known targets
in MEP pathway. The developed model, indeed, have a scope of
improvement as it encourages to generate new experimental data
on P. falciparum enzymes, however the qualitative results would
remain more or less same as obtained from the current model. This
study also provides two distinctive mechanisms of action leading
to killing of the malarial parasite: (1) reducing the ﬂux through
the pathway by inhibiting enzymes having high ﬂux control coef-
ﬁcient (DXS & DXR inhibition), and (2) increasing the accumulation
of toxic metabolite (MECPPS & HMBPPS inhibition), and guides the
design of experiments for further validation.
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